Lupus Nephritis Clinical Trials

19 studies are recruiting for lupus nephritis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. VIBRANT: VIB4920 for Active Lupus Nephritis

   This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology, La Jolla, California

   Locations

   17 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT05201469 on ClinicalTrials.gov

2. The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

   The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily …

   Stage

   Phase 2

   Ages

   8 to 20

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   19 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT05538208 on ClinicalTrials.gov

3. A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

   The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participa…

   Stage

   Phase 2

   Ages

   12 to 70

   Site

   Wallace Rheumatic Studies Center, Beverly Hills, California

   Locations

   12 in total

   Run by

   Fate Therapeutics

   See if you can join NCT07570862 on ClinicalTrials.gov

4. Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

   The purpose of this up to 6-year extension study is the evaluation of the efficacy and safety 1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response [CRR] or partial renal response [PRR]) on double-blind treatment at the end of the S…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   Circuit Clinical, Orchard Park, New York

   Locations

   49 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06711887 on ClinicalTrials.gov

5. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

   This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label…

   Stage

   Phase 2

   Ages

   5 to 17

   Site

   Loma Linda University health, Loma Linda, California

   Locations

   43 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT05039619 on ClinicalTrials.gov

6. A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

   This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopa…

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   Stanford University Medical Center, Redwood City, California

   Locations

   16 in total

   Run by

   CRISPR Therapeutics

   See if you can join NCT06925542 on ClinicalTrials.gov

7. RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   University of California Irvine, Orange, California

   Locations

   23 in total

   Run by

   Cabaletta Bio

   See if you can join NCT06121297 on ClinicalTrials.gov

8. Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

   The purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN).

   Stage

   Phase 2

   Ages

   12 to 65

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   15 in total

   Run by

   Autolus Limited

   See if you can join NCT07053800 on ClinicalTrials.gov

9. PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

   The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).

   Stage

   Phase 4

   Ages

   18 to 75

   Site

   Purushotham & Akther Kotha MD, Inc., La Mesa, California

   Locations

   27 in total

   Run by

   Aurinia Pharmaceuticals Inc.

   See if you can join NCT07611214 on ClinicalTrials.gov

10. Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

    The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

    Stage

    Phase 2

    Ages

    18 to 100

    Site

    Ronald Reagan UCLA Medical Center, Los Angeles, California

    Locations

    103 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT05268289 on ClinicalTrials.gov

11. Wellness & Workforce Solution for Lupus/Lupus Nephritis

    The investigators will test the hypothesis that culturally congruent coaching delivered via a technology application (Health360x) will improve the persistent disparities observed among women of color with lupus or lupus nephritis by addressing underlying psychosocial barriers to behavioral change.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Morehouse School of Medicine, Atlanta, Georgia

    Run by

    Morehouse School of Medicine

    See if you can join NCT06217107 on ClinicalTrials.gov

12. Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

    The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservati…

    Stage

    Not phased

    Ages

    18 and older

    Site

    GSK Investigational Site, Baltimore, Maryland

    Locations

    7 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT06527872 on ClinicalTrials.gov

13. US Zamto-cel Autoimmune Diseases

    AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Miltenyi Biomedicine GmbH

    See if you can join NCT06708845 on ClinicalTrials.gov

14. A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

    This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Nkarta Investigational Site, Little Rock, Arkansas

    Locations

    19 in total

    Run by

    Nkarta, Inc.

    See if you can join NCT06557265 on ClinicalTrials.gov

15. A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

    This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antine…

    Stage

    Phase 1

    Ages

    12 to 70

    Site

    Wallace Rheumatic Center, Beverly Hills, California

    Locations

    21 in total

    Run by

    Fate Therapeutics

    See if you can join NCT06308978 on ClinicalTrials.gov

16. Lupus Landmark Study: A Prospective Registry and Biorepository

    The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).

    Stage

    Not phased

    Ages

    18 to 110

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    25 in total

    Run by

    Lupus Research Alliance

    See if you can join NCT05934149 on ClinicalTrials.gov

17. Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

    The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the dis…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    2 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06434363 on ClinicalTrials.gov

18. Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

    This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) co…

    Stage

    Phase 4

    Ages

    18 to 80

    Site

    AARA Clinical Research, Glendale, Arizona

    Locations

    7 in total

    Run by

    NephroNet, Inc.

    See if you can join NCT07225387 on ClinicalTrials.gov

19. Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

    A central goal of this data repository is to collect data from a large population of subjects with a variety of renal disease states. Cohorts will include subjects with diabetes, inflammatory/autoimmune and transplant related renal conditions. Additionally, the repository will have the capacity to …

    Stage

    Not phased

    Ages

    18 and older

    Site

    The Rogosin Institute, New York, New York

    Run by

    The Rogosin Institute

    See if you can join NCT01802034 on ClinicalTrials.gov